详情页

当前位置：首页 > 详情页

The Potential Clinical Application of Comprehensive Genomic Profiling in Targeted Therapy and Immunotherapy of Lung Cancer

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]The First Affiliated Hospital of Guangxi Medical University, Guangxi/CN, [2]The First Affiliated Hospital, School of Medicine, Zhejiang University,Hangzhou/CN, [3]Fourth Hospital of Hebei Medical University,Shijiazhuang/CN, [4]The Third Affiliated Hospital of Kunming MedicalUniversity, Kunming/CN, [5]The Second Hospital of Dalian MedicalUniversity, Dalian/CN, [6]Zhejiang University International Hospital,Shulan (Hangzhou) Hospital, Hangzhou/CN, [7]Origimed, Shanghai/CN

出处：

ISSN：

关键词： TMB PD-1 blockade immunotherapy MSI

语种：

WOS：

中科院分区：

出版当年[2017]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2017]版：

Q1 RESPIRATORY SYSTEM Q1 ONCOLOGY

最新[2024]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 20.8 最新[2024版] 18.4 最新五年平均 10.34 出版当年[2017版] 7.296 出版当年五年平均 6.595 出版前一年[2016版] 12.46 出版后一年[2018版]

第一作者：

第一作者机构： [1]The First Affiliated Hospital of Guangxi Medical University, Guangxi/CN,

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Epigenetic modulation combined with PD-1/PD-L1 blockade enhance immunotherapy based on MAGE-A11 antigen specific CD8(+)T cells [2]Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8(+)T cells against esophageal carcinoma [3]SYK gene mutations with TMB-H and MSI-H in solid tumors. [4]SYK gene mutations with TMB-H and MSI-H in solid tumors [5]Registry Study in MSI/dMMR Solid Tumors [6]Amplification of the human epidermal growth factor receptor 2 (HER2) gene is associated with a microsatellite stable status in Chinese gastric cancer patients. [7]The Landscape of RET Genomic Alterations in Chinese Non-Small Cell Lung Cancer Patients [8]The Correlation Among PD-L1 Expression, TMB and Lung Immune Prognostic Index in Chinese Patients with Advanced Lung Adenocarcinoma [9]肺癌免疫治疗中肿瘤突变负荷(TMB)临床指导意义的研究进展 [10]Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers